View Item 

Show simple item record

Effects of depressive symptomatology on cancer‐related symptoms during oral oncolytic treatment
dc.contributor.authorDecker, Veronica
dc.contributor.authorSikorskii, Alla
dc.contributor.authorGiven, Charles W.
dc.contributor.authorGiven, Barbara A.
dc.contributor.authorVachon, Eric
dc.contributor.authorKrauss, John C.
dc.date.accessioned2019-02-12T20:25:11Z
dc.date.available2020-03-03T21:29:36Zen
dc.date.issued2019-01
dc.identifier.citationDecker, Veronica; Sikorskii, Alla; Given, Charles W.; Given, Barbara A.; Vachon, Eric; Krauss, John C. (2019). "Effects of depressive symptomatology on cancer‐related symptoms during oral oncolytic treatment." Psycho‐Oncology 28(1): 99-106.
dc.identifier.issn1057-9249
dc.identifier.issn1099-1611
dc.identifier.urihttps://hdl.handle.net/2027.42/147865
dc.description.abstractObjectiveThis manuscript assesses association between depressive symptoms and symptoms from cancer and its treatment during the first 12 weeks of a new oral oncolytic treatment.MethodsThis secondary analysis used data from a recently completed trial of an intervention to improve adherence to oral oncolytic treatment and manage symptoms. Following the initiation of the new oral oncolytic medication, 272 patients were interviewed at intake and weeks 4, 8, and 12 to assess depressive symptoms, and symptoms from cancer and its treatment. Depressive symptoms were measured using the Center for Epidemiologic Studies‐Depression (CES‐D20). The summed index of 18 cancer‐related and treatment‐related symptoms as well as the number of symptoms above threshold at intake, weeks 4, 8, and 12 were related to intake and time‐varying CES‐D20 using linear mixed effects models.ResultsDepressive symptomatology was a significant predictor of cancer‐related and treatment‐related symptoms at all‐time points, but the strength of this relationship was greatest at the time of oral oncolytic agent initiation and at week 4. The strength of this relationship was the same for both summed symptom severity index and the number of symptoms above threshold, and using either intake or time‐varying CES‐D20.ConclusionIntroducing strategies to treat and manage symptoms of depression along with other symptoms might have added benefits among patients who start a new oral oncolytic treatment and report modest to higher levels of depressive symptoms. Assessments for the impact of strategies to lower depressive symptoms can be taken within the first 4 weeks.
dc.publisherMichigan State University
dc.publisherWiley Periodicals, Inc.
dc.subject.otheroncology
dc.subject.otheroral agents
dc.subject.otherdepression
dc.subject.othercancer
dc.subject.othersymptoms
dc.titleEffects of depressive symptomatology on cancer‐related symptoms during oral oncolytic treatment
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/147865/1/pon4916.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/147865/2/pon4916_am.pdf
dc.identifier.doi10.1002/pon.4916
dc.identifier.sourcePsycho‐Oncology
dc.identifier.citedreferenceFirst MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM‐IV‐TR Axis I Disorders, Research Version, Non‐Patient Edition. Biometric Research Department, New York State Psychiatric Institute; 2002.
dc.identifier.citedreferencePasquini M, Biondi M. Depression in cancer patients: a critical review. Clin Pract Epidemiol Ment Health. 2007; 3 ( 1 ): 2.
dc.identifier.citedreferenceLi M, Fitzgerald P, Rodin G. Evidence‐based treatment of depression in patient with cancer. J Clin Oncol. 2012; 30 ( 11 ): 1187 ‐ 1196. https://doi.org/10.1200/JCO.2011.39.7372
dc.identifier.citedreferenceHermelink K, Kuchenhoff H, Untch M, et al. Two different sides of ‘chemobrain’: determinates and nondeterminates of self‐perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psychooncology. 2010; 19 ( 12 ): 1321 ‐ 1328. https://doi.org/10.1002/pon.1695
dc.identifier.citedreferenceNational Comprehensive Cancer Network. NCCN clinical practice guidelines in Oncology, Version 2.2016; 2016. Fort Washington, PA: National Comprehensive Cancer Network; c2018 [Cited 2018 June 25]. https://www.nccn.org/professionals/physician_gls/default.aspx
dc.identifier.citedreferenceGiven BA, Given CW, Majeske C. Medication Management and Symptom Management Toolkit. East Lansing MI: Michigan State University; 2013.
dc.identifier.citedreferenceSikorskii A, Given CW, Given BA, et al. An automated intervention did not improve adherence to oral oncolytic agents while managing symptoms: results from a two‐arm randomized controlled trial. J Pain Symptom Manage. 2018. August Epub before print. https://doi.org/10.1016/j.jpainsymman.2018.07.021
dc.identifier.citedreferenceRadloff LS. The CES‐D20 Scale: a self‐report depression scale for research in the general population. Appl Psychol Measur. 1977; 1 ( 3 ): 385 ‐ 401.
dc.identifier.citedreferenceCarleton RN, Thibodeau MA, Teale MJ, et al. The center for epidemiologic studies depression scale: a review with a theoretical and empirical examination of item content and factor structure. PLoS One. 2013; 8 ( 3 ): e58067. https://doi.org/10.1371/journal.pone.0058067
dc.identifier.citedreferenceSegrin C, Badger T, Dorros SM, Meek P, Lopez AM. Interdependent anxiety and psychological distress in women with breast cancer and their partners. Psychooncology. 2007; 16 ( 7 ): 634 ‐ 643.
dc.identifier.citedreferenceVilagut G, Forero CG, Barbaglia G, Alonso J. Screening for depression in the general population with the Center for Epidemiologic Studies Depression (CES‐D20): a systematic review with meta‐analysis. PLoS One. 2016; 11 ( 5 ): e0155431. https://doi.org/10.1371/journal.pone.0155431
dc.identifier.citedreferencePROsetta Stone Linking Tables. [website]. Illinois: David Cella, Ph.D., Department of Medical Social Sciences at the Feinberg School of Medicine, Northwestern University [Cited 2018 June 25]. http://www.prosettastone.org/LinkingTables1/Pages/default.aspx
dc.identifier.citedreferenceGiven B, Given C, Sikorskii A, et al. Establishing mild, moderate and severe scores for cancer related symptoms: how consistent and clinically meaningful are interference based severity cut points? J Pain Symptom Manage. 2008; 35 ( 2 ): 126 ‐ 135.
dc.identifier.citedreferenceNipp RD, El‐Jawahri A, Moran SM, et al. The relationship between physical and psychological symptoms and health care utilization in hospitalized patients with advanced cancer. Cancer. 2017; 123 ( 23 ): 4720 ‐ 4727. https://doi.org/10.1002/cncr.30912.
dc.identifier.citedreferenceSikorskii A, Given C, Given B, et al. Symptom management for cancer patients: a trial comparing two multimodal interventions. J Pain Symptom Manage. 2007; 34 ( 3 ): 253 ‐ 264.
dc.identifier.citedreferenceSikorskii A, Given C, Given B, et al. Do treatment patterns alter beliefs cancer patients hold regarding oral oncolytic agents? Psychooncology. 2018; 27 ( 3 ): 1005 ‐ 1012. https://doi.org/10.1002/pon.4606
dc.identifier.citedreferenceClover K, Lambert SD, Oldmeadow C, et al. PROMIS depression measures perform similarly to legacy measures relative to a structured diagnostic interview for depression in cancer patients. Qual Life Res. 2018; 27 ( 5 ): 1357 ‐ 1367. https://doi.org/10.1007/s11136‐018‐1803‐x
dc.identifier.citedreferencevan Wilgen CP, Dijkstra PU, Stewart RE, Ranchor AV, Roodenburg JL. Measuring somatic symptoms with the CES‐D20 to assess depression in cancer patients after treatment: comparison among patients with oral/oropharyngeal, gynecological, colorectal, and breast cancer. Psychosomatics. 2006; 47 ( 6 ): 465 ‐ 470.
dc.identifier.citedreferenceHealth measures [homepage on the internet]. Illinois: Northwestern University [Cited 2018 June 25]. Healthmeasures.net
dc.identifier.citedreferenceCleeland CS, Sloan JA, Cella D, et al. CPRO (assessing the symptoms of cancer using patient‐reported outcomes) multisymptom task force. Recommendations for including multiple symptoms as endpoints in cancer clinical trials: a report from the ASCPRO (assessing the symptoms of cancer using patient‐reported outcomes) multisymptom task force. Cancer. 2013; 119 ( 2 ): 411 ‐ 420. https://doi.org/10.1002/cncr.27744
dc.identifier.citedreferenceCleeland CS, Zhao F, Chang VT, et al. The symptom burden of cancer: evidence for a core set of cancer‐related and treatment‐related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer. 2013; 119 ( 24 ): 4333 ‐ 4340. https://doi.org/10.1002/cncr.28376
dc.identifier.citedreferenceHillman SL, Mandrekar SJ, Bot B, et al. Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation. J Clin Oncol. 2010; 28 ( 18 ): 3002 ‐ 3007. https://doi.org/10.1200/JCO.2009.27.4282
dc.identifier.citedreferenceVoils CI, King HA, Maciejewski ML, Allen KD, Yancy WS Jr, Shaffer JA. Approaches for informing optimal dose of behavioral interventions. Ann Behav Med. 2014; 48 ( 3 ): 392 ‐ 401. https://doi.org/10.1007/s12160‐014‐9618‐7
dc.identifier.citedreferenceCaruso R, Nanni MG, Riba M, et al. Depressive spectrum disorders in cancer: prevalence, risk factors and screening for depression: a critical review. Acta Oncol. 2017; 56 ( 2 ): 146 ‐ 155.
dc.identifier.citedreferenceSmith HR. Depression in cancer patients: pathogenesis, implications and treatment (review). Oncol Lett. 2015; 9 ( 4 ): 1509 ‐ 1514.
dc.identifier.citedreferenceGanz PA. Monitoring the physical health of cancer survivors: a survivorship‐focused medical history. J Clin Oncol. 2006; 24 ( 32 ): 5105 ‐ 5111.
dc.identifier.citedreferenceOstuzzi G, Matcham F, Dauchy S, Barbui C, Hotopf M. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev. 2015; 6. CD011006. doi: https://doi.org/10.1002/14651858.CD011006.pub2
dc.identifier.citedreferencePrieto JM, Blanch J, Atala J, et al. Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem‐cell transplantation. J Clin Oncol. 2002; 20 ( 7 ): 1907 ‐ 1917. https://doi.org/10.1200/JCO.2002.07.101
dc.identifier.citedreferenceArrieta O, Angulo LP, Núñez‐Valencia C, et al. Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non‐small cell lung cancer. Ann Surg Oncol. 2013; 20 ( 6 ): 1941 ‐ 1948. https://doi.org/10.1245/s10434‐012‐2793‐5
dc.identifier.citedreferenceDiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta‐analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000; 160 ( 14 ): 2101 ‐ 2107.
dc.identifier.citedreferenceWalker J, Hansen CH, Martin P, et al. Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross‐sectional analysis of routinely collected clinical data. Lancet Psychiatry. 2014; 1 ( 5 ): 343 ‐ 350. https://doi.org/10.1016/S2215‐0366(14)70313‐X
dc.identifier.citedreferenceChan A, Ng TR, Yap KY. Clinically‐relevant anticancer‐antidepressant drug interactions. Expert Opin Drug Metab Toxicol. 2012; 8 ( 2 ): 173 ‐ 199. https://doi.org/10.1517/17425255.2012.645804
dc.identifier.citedreferenceNavari RM, Brenner MC, Wilson MN. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat. 2008; 112 ( 1 ): 197 ‐ 201. https://doi.org/10.1007/s10549‐007‐9841‐z
dc.identifier.citedreferencePinquart M, Duberstein PR. Depression and cancer mortality: a meta‐analysis. Psychol Med. 2010; 40 ( 11 ): 1797 ‐ 1810. https://doi.org/10.1017/S0033291709992285
dc.identifier.citedreferenceMiaskowski C, Dunn L, Ritchie C, et al. Latent class analysis reveals distinct subgroups of patients based on symptom occurrence and demographic and clinical characteristics. J Pain Symptom Manage. 2015; 50 ( 1 ): 28 ‐ 37.
dc.identifier.citedreferenceCiaramella A, Poli P. Assessment of depression among cancer patients: the role of pain, cancer type and treatment. Psychooncology. 2001; 10 ( 2 ): 156 ‐ 165. https://doi.org/10.1002/pon.505
dc.identifier.citedreferenceUchitomi Y, Mikami I, Nagai K, Nishiwaki Y, Akechi T, Okamura H. Depression and psychological distress in patients during the year after curative resection of non‐small‐cell lung cancer. J Clin Oncol. 2003; 21 ( 1 ): 69 ‐ 71. https://doi.org/10.1200/JCO.2003.12.139
dc.identifier.citedreferenceSaracino RM, Weinberger MI, Roth AJ, Hurria A, Nelson CJ. Assessing depression in a geriatric cancer population. Psychooncology. 2017; 26 ( 10 ): 1484 ‐ 1490. https://doi.org/10.1002/pon.4160
dc.identifier.citedreferenceWakefield C, Butow PN, Aaronson NA, Hack TF, Hubert‐Williams NJ, Jacobsen PB. Patient‐reported depression measures in cancer: a meta‐review. Lancet Psychiatry. 2015; 2 ( 7 ): 635 ‐ 647. https://doi.org/10.1016/S2215‐0366(15)00168‐6
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
pon4916.pdf
Size:
675.3KB
Format:
PDF
View/Open
Name:
pon4916_am.pdf
Size:
254.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.